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Available online 4 February 2013Monoclonal κ and λ immunoglobulin free light chain (FLC) paraproteins in serum and urine
are important markers in the diagnosis and monitoring of B cell dyscrasias. Current
nephelometric and turbidimetric methods that use sheep polyclonal antisera to quantify
serum FLC have a number of well-observed limitations. In this report, we describe an improved
method using specific mouse anti-human FLC monoclonal antibodies (mAbs). Anti-κ and
anti-λ FLC mAbs were, separately, covalently coupled to polystyrene Xmap® beads and
assayed, simultaneously, in a multi-plex format by Luminex® (mAb assay). The mAbs
displayed no cross-reactivity to bound LC, the alternate LC type, or other human proteins and
had improved sensitivity and specificity over immunofixation electrophoresis (IFE) and
Freelite™. The assay gives good linearity and sensitivity (b1 mg/L), and the competitive
inhibition format gave a broad calibration curve up to 437.5 mg/L and prevented anomalous
results for samples in antigen excess i.e. high FLC levels. The mAbs displayed good concordance
with Freelite™ for the quantitation of normal polyclonal FLC in plasma from healthy donors
(n = 249). The mAb assay identified all monoclonal FLC in serum from consecutive patient
samples (n = 1000; 50.1% with monoclonal paraprotein by serum IFE), and all FLC in a large
cohort of urine samples tested for Bence Jones proteins (n = 13090; 22.8% with monoclonal κ,
9.0% with monoclonal λ, and 0.8% with poly LC detected by urine IFE). Importantly this shows
that the mAbs are at least close to the ideal of detecting FLC from all patients and neoplastic
plasma cell clones. Given the overall effectiveness of the anti-FLC mAbs, further clinical
validation is now warranted on serial samples from a range of patients with B cell disorders.
Use of these mAbs on other assay platforms should also be investigated.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
Multiple myeloma
Serum free light chains
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Plasma cell dyscrasias1. Introduction
The total of body plasma cells secretes about 1 g per day
of kappa and lambda immunoglobulin free light chains
(FLCs) into the extracellular fluids. These FLCs are cleared
from the blood by glomerular filtration with a half-life of 2 to
6 h (Waldmann et al., 1972). A neoplastic clone of plasma
cells must secrete up to 20 g of FLC per day to saturateyson).
 BY-NC-ND license.FLC absorption in the proximal renal tubules of healthy
kidneys and thus become detectable in urine (Drayson,
2012). Accordingly it would be preferable to detect and
quantitate FLC in blood not urine but this is difficult because
serum levels of FLC are mg/L compared to the one thousand-
fold higher level of LC bound to whole immunoglobulin.
Antibodies for routine clinical quantitation of serum FLCmust
have specificity for epitopes that are exposed on FLC and
hidden on LC bound in whole immunoglobulin; further these
antibodies must detect FLC from all patients and neoplastic
plasma cell clones.
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FLC assays (Freelite™, the Binding Site Ltd., UK) (Bradwell et al.,
2001). These immunoassays employ purified specific sheep
polyclonal antisera adsorbed to render them specific for κ
and λ FLCs, respectively, that are latex-enhanced for use in
turbidimetric and nephelometric immunoassays. For the first
time it has been possible to routinely measure serum FLCs
from an array of patient groups that includes oligosecretory
myeloma (Drayson et al., 2001), light chain only myeloma
(Bradwell et al., 2003), light chain amyloidosis (Lachmann
et al., 2003), monoclonal gammopathy of unknown signifi-
cance (MGUS) (Rajkumar et al., 2004), healthy individuals
(Katzmann et al., 2002), and others (Drayson, 2012). Dual
measurement of serum κ and λ FLC levels has also highlighted
the importance of the κ:λ ratio in the diagnosis andmonitoring
of B cell malignancies. The κ:λ ratio represents a sensitive
balance between the two light chain types, whereby over-
production of one type by a malignant B cell clone leads to a
perturbation of the normal κ:λ reference range (Freelite™ κ:λ
ratio = 0.26–1.65 (Katzmann et al., 2002)). It is now possible
to identify patients with a perturbed serum κ:λ ratio before
disease has progressed to the extent that Bence Jones (BJ)
protein appears in urine. The serum FLC ratio facilitates
diagnosis and monitoring of oligosecretory myeloma and
light chain amyloid where serum and urine immunofixation
is negative, enables earlier diagnosis of active light chain
only disease, reducing the risk of acute kidney damage
(Hutchison et al., 2008) and gives prognostic information in
all B cell dyscrasias and in healthy individuals (Dispenzieri
et al., 2012).
These clinically significant developments arewell established
and international guidelines recommend the use of Freelite™ in
diagnosis and management of a wide range of plasma cell
dyscrasias (Dispenzieri et al., 2009). However, this first gener-
ation of serum FLC assays has technical limitations. A separate
test for each κ and λ FLC measurement is required, introducing
inter-test error and reducing the reliability of the κ:λ ratio result
obtained. This variability is compounded further by the batch-
to-batch differences observed in the polyclonal antisera pro-
duced from individual sheep (Tate et al., 2007, 2009). In clinical
practise, it is important to detect both the elevation of one FLC
type by secretion of malignant FLC and the reduction in levels of
the alternate FLC by immunoparesis. Thus assays need to
quantitate FLC levels ranging from 1 mg/L to >1000 mg/L.
The latex-enhanced antisera have a calibration range of 3.7–
56.2 mg/L for κ FLC and 5.6–74.8 mg/L for λ FLC, and are
unreliable at the lower end. This can lead to an abnormal κ:λ
ratio in healthy individuals and apparently significant changes in
ratio between sequential samples from myeloma patients who
are in fact still in remission. This problem is highlighted by ‘gaps’
above and below the working calibration range of the assay
(Bradwell, 2008). The limited calibration range also requires that
samples with high FLC be diluted several times. The assay is
prone to antigen-excess (or “hook effect”) which can cause
false negative diagnoses in patients with grossly elevated FLC
and false positive evidence of disease progression (Daval et al.,
2007; Levinson, 2010a; Murata et al., 2010). Monoclonal FLC
paraproteins tested on Freelite™ have been shown to be non-
linear (Tate et al., 2007) meaning that dilutions could lead to
inaccurate FLC quantitation. The polyclonal antisera in the assay
are targeted against polyclonal FLC, as opposed to monoclonalFLC, potentiating the claim that the Freelite™ sensitivity to
paraprotein levels slightly outside the normal reference range is
negatively affected (Levinson, 2010b). Further, there are reports
that the antisera are cross-reactive with bound κ and λ LC
(Davern et al., 2008) leading to excessively high FLC results not
representative of absolute FLC levels. A second generation of
serum FLC tests is needed to overcome these problems. If
monoclonal antibodies (mAbs) could be produced that specif-
ically target human κ and λ FLCs, then they would provide a
long term solution to the problems of the current polyclonal
Freelite™ assay.
Development of FLC specific mAbs is difficult and compli-
cated by the paucity of constant domain epitopes available for
FLC recognition; which can be further reduced by polymerisa-
tion of FLC, particularly FLC λ, thus reducing the number of
potential binding sites (Abraham et al., 2002; Bergen et al.,
2004; Davern et al., 2008). Production of mAbs specific for FLC
has been described previously (Abe et al., 1993, 1998; Nakano
and Nagata, 2003; Davern et al., 2008) and these groups have
demonstrated mAb specificity for epitopes that are exposed on
FLC and hidden on LC bound in whole immunoglobulin.
However these groups have either found that their mAbs did
not detect FLC from all neoplastic plasma cell clones tested or
have not tested sufficient clones to be confident that the mAbs
would detect the FLC from at least 95% of neoplastic clones.
Recently another group reported anti-FLC mAbs (te Velthuis
et al., 2011; Hoedemakers et al., 2012) again, specificity with at
least 95% of neoplastic FLC clones appears unlikely, especially
for λ FLC (Drayson and Carr-Smith, 2012; Hutchison et al.,
2012).
In the present study, we describe the development and
initial validation of two anti-κ FLC and two anti-λ FLC mAbs
in a competitive-inhibition multi-plex Luminex® assay (mAb
assay). Whilst it is important that the new assay overcomes
the problems with existing commercial assays, initial clinical
validation must also demonstrate that the mAbs provide: (1)
similar quantitation of polyclonal FLC from healthy donors to
the Freelite™ assay; (2) appropriate sensitivity to reliably
quantify low levels of FLC representative of immunosuppres-
sion or immunoparesis; and (3) by testing a large number of
serum and urine samples it shows that the mAbs are at least
close to the ideal of detecting FLC from all patients and
neoplastic cell clones.
2. Materials and methods
2.1. Ethical approval
Ethical approval for development and validation of the
FLC assay using residual, end-of-diagnostic use of patient
serum and urine was granted by the Life and Health
Sciences Ethical Review Committee of the University of
Birmingham, UK. Financial support for the study was
provided by the Clinical Immunology Service, University of
Birmingham, UK.
2.2. Preparation of anti-FLC mAbs
Anti-FLC mAbs were prepared using standard methods
(Galfre and Milstein, 1981). Briefly, BALB/c mice were
immunised with κ or λ FLC purified from human urine
3J.P. Campbell et al. / Journal of Immunological Methods 391 (2013) 1–13containing BJ Protein or immunoglobulin fragments. Spleens
from immunised mice were dispersed into single cell suspen-
sions, mixed with immortal mouse plasmacytoma cells (NSI,
NSO) and fusions of cells facilitated with polyethylene glycol
(PEG). The cell mixture was plated out in 96 well plates with
selection being facilitated with hypoxanthine, thymidine, and
methotrexate. Supernatants fromwells containing clones were
assayed for production of antibodies specific for κ or λ FLC.
Anti-FLC mAbs were selected based on reactivity with a large
panel of κ or λ FLC antigens containing a variety of variable
and constant regions, and shown to be negative for alternate
FLC, light chains bound to immunoglobulins of all classes
and subclasses, albumin and other selected human serum
proteins. Initial assays were performed in haemagglutination
and haemagglutination inhibition assays where sheep red
blood cells were coupled to purified FLC from individual
patients (Ling et al., 1977). Ascites cells were adapted
to in vitro culture, and were expanded in a mini-perm
bioreactor. Bioreactor supernatants (MiniPerm, Sarstedt)
containing anti-FLC mAbs were purified using protein G or
SpA chromatography (GE Healthcare). Purified mAb collec-
tions were diluted 1/100 and quantified by spectropho-
tometry (Eppendorf) at 280 nm for protein concentration,
with 1.43 extinction coefficient (Hay et al., 2002). Initially,
anti-FLC mAbs were selected based on reactivity with all
κ or λ FLC antigens in a panel of different BJ proteins,
and minimal cross-reactivity to a panel of purified whole
immunoglobulins. Specificity was established by covalently
coupling mAbs to Luminex® Xmap® beads (Bio-Rad, UK)
and quantifying polyclonal light chains from dithiothreitol
treated immunoglobulin infusate (Gammagard Liquid), which
was then reduced and/or acetylated and separated on a G100
column in the presence of proprionic acid, and quantified using
Freelite™. In addition, specificity was established on the
Luminex® against: (a) a panel of serum samples from patients
with elevated polyclonal light chains and myeloma; and, (b) a
panel of urine samples containingBJ proteins. From this process,
two anti-κ (BUCIS 01 and BUCIS 04) and two anti-λ (BUCIS 03
and BUCIS 09) FLC mAbs were chosen for further development
and initial validation in the mAb assay (Serascience, UK).
2.3. Preparation of calibrator material
Individual urines containing a high level of BJ protein
were centrifuged and 0.2 μm filtered. Purity assessment
was conducted by SDS Page and those identified as showing
a single band of monomeric FLC and/or single band of dimeric
FLC, indicating that there were no other proteins visible, were
dialysed against deionised water with several changes of
water. Each preparation was passed over activated charcoal,
concentrated by vacuum dialysis, and freeze-dried on a
vacuum dryer and protein stored at 4 °C. Calibrator material
was made by combining four sources of purified BJ λ protein
and five sources of BJ κ protein. 105 mg of each FLC pro-
tein was dissolved in 15 mL saline, overnight at 4 °C. The
supernatants were 0.2 μm filtered before measuring the
concentration by spectrophotometry at 280 Å at a dilution
of 1/100 and extinction coefficient of 11.8 (Hay et al., 2002).
Equal amounts of each BJ κ or λ protein were combined and
the volumes of the two preparations were adjusted with
sterile PBS to a concentration of 7 mg/mL. Sodium azide wasadded from a 0.2 μm filtered preparation of 9.9% w/v in
deionised water to give a final concentration of 0.099%. The
preparations were aliquoted into 1 mL volume and stored
at −80 °C.
2.4. Biotinylation of immunoglobulin free light chains
For the purposes of a competitive inhibition assay,
individual κ and λ FLC mixes were biotinylated for later
binding to streptavidin-PE in the assay phase, as follows.
Purified κ and λ FLC calibrator materials were separately
incubated with biotinamidohexanoyl-6-aminohexanoic acid,
N-hydroxysuccinimide ester in dimethyl sulfoxide overnight
(all Sigma Aldrich). Biotinylated light chains were then
separated using NAP™ 5 Columns (Sephadex G-25 DNA
grade; GE Healthcare), eluted in PBS, and the concentration
of the eluate was measured by spectrophotometry. After the
addition of 0.099% sodium azide, biotinylated light chains
were stored at 4 °C, until required.
2.5. Luminex® bead—mAb couplings
Prior to assaying, each of the anti-κ FLC and anti-λ
FLC mAbs was covalently coupled to four different 5.5 μm
polystyrene Xmap® beads (Bio-Rad UK) using a two step
carbodiimide reaction protocol. Specifically, the different
bead regions used were #27 (BUCIS 01), #28 (BUCIS 04),
#29 (BUCIS 03), and #30 (BUCIS 09). After sonication and
vortexing, beads were incubated with N-hydroxysuccinimide
(NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC) for 30 min in activation buffer (0.1 M
PBS, pH 6.2). Following two wash procedures, the bead pellet
was incubated for 3 h with the relevant mAbs (100 μL at
1 mg/mL) on a rotor, in the dark, at room temperature.
Beads were then washed twice, and finally, the pellet was
resuspended in blocking/storage buffer (0.1 M PBS, 0.05%
Tween20, 1% BSA, 0.05% NaN3, pH 7.2). The beads were
enumerated using a haemocytometer to ensure consistency
between conjugations. Labelled beads were stored in blocking/
storage buffer in the dark at 4 °C until required in the assay; the
beads were found to be stable for at least 6 months in these
conditions (data not shown).
The efficiency of mAb conjugation to each beadset was
determined in a one-step assay by incubating each beadset
with goat anti-mouse IgG labelled with phycoerythrin (PE;
Southern Biotech, USA), and subsequent measurement by
Luminex®. The effectiveness of each mAb-bead complex at
detecting κ and λ FLCs was tested in a two-step assay by (1)
incubating beads with biotinylated purified κ and λ FLCs, and
(2) incubation with streptavidin-PE (Invitrogen, UK), and
subsequent measurement by Luminex®. A minimummedian
fluorescent intensity (mfi) was set at >10,000 mfi units for
mAb conjugation to beads and >5000 mfi units for detection
of κ and λ FLCs, as this provided calibration curves with
the most sustained linearity, and, hence, more reliable and
reproducible results on patient samples.
2.6. mAb assay for measurement of κ and λ FLCs
Human κ and λ FLCs were measured in a multi-plex
competitive inhibition format. 40 μl of biotinylated FLC
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0.099% NaN3, 0.05% Tween20) was added to each well in a
1.2 μm MV Multiscreen (Millipore, UK) 96-well filter plate,
followed by 40 μl of each sample, calibrators or controls, and
then incubated for 30 min with mAb coupled beads. Each
sample was diluted 1 in 5 in assay buffer (PBS, 1% BSA, 0.05%
NaN3) prior to addition to the filter plate. A seven-point
calibration curve with a five parameter logistical curve fitting
was used (BioPlex Manager 6.0, BioRad UK). The calibration
material was generated by mixing an equal amount of the
stock κ and λ FLC material, and then diluting this 1 in 8 in FLC
buffer to give the starting calibration point (437.5 mg/L). The
top calibrator was then serially diluted 4-fold in FLC buffer
to 0.1 mg/L, in duplicate. In-house quality controls were
used on all assay plates to monitor assay performance and
reproducibility. Following incubation for 30 min, filter plates
were washed three times using assay buffer and aspirated
using a manifold pump. 50 μl streptavidin-PE (diluted 1 in
500 in assay buffer) was added to all wells and incubated for
30 min. After further washing, plates were analysed on a
Luminex® 100 system (Luminex Corp., USA). A minimum of
100 beads per bead region, per well of the filter plate, were
counted on the Luminex®. Samples exhibiting a high FLC
concentration above the initialworking range of the calibration
curve at a 1 in 5 dilution, were repeated at a 1 in 100 dilution
in assay buffer, to avoid extrapolation and ensure reliable1
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Fig. 1. Representative calibration curves showing the median fluorescen
intensity (mFI) and FLC concentration (mg/L) generated by the mAb assay
for each anti-κ FLC mAb (BUCIS 01 and BUCIS 04) and each anti-λ FLC mAb
(BUCIS 03 and BUCIS 09). These representative curves included a calibration
coefficient that was applied to each mAb, as described in Section 2.7. Briefly
the process of applying a calibration coefficient began by conducting an
initial method comparison between each anti-FLC mAb and Freelite™ on
249 healthy donor plasma samples, to investigate whether each anti-FLC
mAbs provided a similar quantitation of polyclonal FLC. From this process, i
was clear that each anti-κ FLC mAb provided different results for polyclona
FLC, and each provided different results to Freelite™; the same was found for
each anti-λ FLC mAb. Hence, it was necessary to use different calibration
coefficients for each mAb to provide similar quantitation of polyclonal FLCs
to Freelite™. Therefore, a calibration coefficient was applied to the calibrator
material (mix of monoclonal FLC from the urine of myeloma patients) results
obtained by spectrophotometry for κ FLC (437.5 mg/L) andλ FLC (437.5 mg/L)
and these were: BUCIS 01 = 0.731X, BUCIS 04 = 3.086X, BUCIS 03 = 0.869X
BUCIS 09 = 1.600X (where X is equal to the spectrophotometry result).t
,
t
l
,
,quantitation of samples on the linear sectors of the standard
curves (see Fig. 1 for representative calibration curves).
2.7. Assignment of a calibration coefﬁcient to the mAb assay
To establish if each anti-κ FLC mAb provided a similar
quantitation of polyclonal κ FLC, and each anti-λ FLC mAb
provided a similar quantitation of polyclonal λ FLC, an initial
method comparison of each mAb was conducted using 249
donor plasma samples from the UK NHSBT. From this process,
it became clear that each anti-κ FLC mAb provided different
results for polyclonal FLC, and subsequent analyses found that
each provided different results to Freelite™; the same was
found for each anti-λ FLCmAb (data not shown). Hence, it was
necessary to use different calibration coefficients for each mAb
to provide similar quantitation of polyclonal FLCs to each other,
and to Freelite™. Final calibration coefficients were derived by
a method comparison (Krouwer et al., 2010) to the Freelite™
assay for polyclonal FLC (Katzmann et al., 2002). Calibration
traceability to Freelite™ was preferred because there is no
recognised international standard for FLC, and to ensure that
the guidelines issued by the International Working Group on
Multiple Myeloma (Dispenzieri et al., 2009) are transferable to
themAb assay, as discussed elsewhere (te Velthuis et al., 2011).
Accordingly, a calibration coefficient was applied to the cal-
ibratormaterial result obtained by spectrophotometry for κ FLC
(437.5 mg/L) and λ FLC (437.5 mg/L). For each anti-FLC mAb,
the following calibration coefficients were applied to the
calibrator material: BUCIS 01 = 0.731X, BUCIS 04 = 3.086X,
BUCIS 03 = 0.869X, BUCIS 09 = 1.600X; where X is equal to
the calibrator result by spectrophotometry. Representative
calibration curves are displayed in Fig. 1.
2.8. Assay dynamics
Assay limit of detection was measured by spiking a pool
of normal plasma samples with no more than 20% volume of
purified BJ κ or λ protein from patient urine. These spiked
samples were serially diluted 1 in 4 in assay buffer and
measured on the mAb assay. Serial dilutions were replicated
five times within the same plate, and the limit of detection
for each mAb was then assessed. The limit of detection for
each mAb was determined by selecting the lowest concen-
tration detected by the mAb assay above the blank well
containing only assay buffer (no BJ protein).
Assay linearitywas assessed by serially diluting three serum
samples containing elevated levels of monoclonal κ FLC and
three samples containing elevated levels of monoclonal λ FLC,
two-fold in assay buffer. These six sampleswere serially diluted
nine times with three replicates of each dilution conducted
within the same plate. Linearity of the mAb assay was then
assessed on the ten sample dilutions. Because competitive
inhibition assays are inherently non-linear, a strategy for
demonstrating linearity was conducted by comparing the
expected results against the acquired results from the serial
dilutions.
Assay batch-to-batch variability was assessed by analysing
fifty serum samples with varying FLC levels once, on separate
assay days, using three consecutive batches of anti-FLC mAbs,
calibrators and other appropriate assay reagents.
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assay coefficient of variation percentage (CV%) and the inter-
assay CV%. For these tests, pools of samples with low, medium
and high levels of κ and λ FLCs were used. All samples were
analysed in duplicate, every morning, for ten working consec-
utive days, and all tests were conducted in accordancewith the
Clinical and Laboratory Standards Institute (CLSI) guideline
EP5-A2 (Tholen et al., 2004).
The susceptibility of the mAb assay to interference was
measured by adding knownquantities of interference agents to
a pool of National Health Service Blood and Transplant Service
(NHSBT) plasma samples containing normal κ (11.12 mg/L)
and λ (7.62 mg/L) FLC levels. Individual aliquots of the
plasma pool were spiked with purified IgG-κ (3.5 g/L), IgG-λ
(3.6 g/L), IgA-κ (1.5 g/L), IgA-λ (3.2 g/L), IgM-κ (6.5 g/L),
IgM-λ (3.7 g/L), haemoglobin (4 g/L), bilirubin (0.2 g/L), cho-
lesterol (2 g/L), triglyceride (5 g/L), as well as κ FLC (2 g/L) or λ
FLC (2 g/L). Interference testing was conducted in accordance
with CLSI guidelines EP7-A2 (McEnroe et al., 2005).
For all tests on assay dynamics, except mAb limit of
detection, the maximal value obtained from each anti-κ FLC
mAb (BUCIS 01 or BUCIS 04) was used as the final κ result,
and the same approach was used for each anti-λ FLC mAb
(BUCIS 03 and BUCIS 09) for λ FLC results.
2.9. Reference values
250 plasma samples obtained from healthy random
donors (NHSBT UK) were measured using the Freelite™ and
mAb assays; results obtained by all four anti-FLC mAbs were
used for these analyses. All samples were first screened for
paraproteins by routine serum immunofixation electropho-
resis (IFE). Results were presented as the 95% reference
populations, as well as the 100% reference range, so as
to allow a comparison to the Freelite™ assay (Katzmann
et al., 2002). To generate the 95% reference results, extreme
outliers three times the size of the inter-quartile range were
removed. Due to a positively skewed distribution after outlier
removal, results were ranked by z-scores to identify the
central 95% intervals.
2.10. Clinical speciﬁcity on patient serum samples and
urine samples
1000 consecutive serum samples received by the Clinical
Immunology Service (CIS) for routine clinical measurement
of κ and λ FLCs (on Freelite™) were analysed simultaneously
on the mAb assay. This exercise served three purposes: to
establish the specificity of each mAb at detecting FLC levels in
patients with a wide range of disease conditions; to make a
comparison with Freelite™; and to serve as a preliminary
assessment of the mAb assay in a clinical setting. 209 sam-
ples were from patients enrolled in myeloma trials. Of the
791 non-trial patient samples, 292 had a known serum
paraprotein, 106 had no paraprotein, and no admission
diagnosis was available for the remaining 393 samples. In
addition, 289 samples had a matched urine sample and 711
samples had no matched urine. Samples were collected
chronologically throughout July and August 2011 as they
arrived at the Clinical Immunology Service, and inclusion
criteria required the sample volume be greater than 500 μL; noother inclusion/exclusion criteria were set. Results generated
by each mAb were compared to the results obtained by
Freelite™. Experimenters were blind to the original Freelite™
result and patient diagnosis. Any discrepant results between
Freelite™ and the mAb assay were repeated on both platforms
to exclude the possibility of user/instrument error. A discrep-
ancywas defined as any samplewith an abnormal κ:λ FLC ratio
on one assay but not the other, or, an elevated FLC concentra-
tion outside the normal 95% reference range on one assay but
not the other (see Fig. 2 for reference ranges). To exclude the
possibility that anti-FLC mAbs ‘missed’ any monoclonal FLC,
any discrepant samples were further investigated by routine
serum IFE analysis, IFE and mAb assay analysis of urine, and
patient history, if available.
The specificity of the anti-FLC mAbs at measuring
FLC levels and ability to detect FLC from all patients was
further tested in a large cohort of urine samples. An initial
comparison was made between the mAb assay and com-
mercially available radial immunodiffusion assays (RID; the
Binding Site, UK). Correlations between the two assays were
good (results not shown) and a further comparison was
made between the mAb assay and densitometric scanning of
protein electrophoresis, regarded as the “gold standard” in
urine FLC paraprotein quantitation. Individual concentrated
urine (30× concentrated; Zeba) was analysed by densitometry
according to the manufacturer's instructions (Interlab, Italy),
total protein (Total Protein Gen.2, Roche) was estimated on a
Roche Hitachi Analyser, and for comparison, FLCs were also
analysed on themAb assay. Results demonstrated that themAb
assay correlated well with densitometry (representative data
in Fig. 3). Given the success of themAb assay at detecting FLC in
urine, the clinical utility of the mAb assay was then assessed in
13,090 unconcentrated urine samples sent to the laboratory for
routine FLC analysis between April 2008 and Nov 2010. All
samples were also analysed by urine IFE (the gold standard for
presence of LC in urine) to assess the specificity of the mAb
assay, and to ensure that the mAb assay detected all FLC
paraproteins. All samples were analysed as they arrived in the
laboratory. After initial routine analyses, samples were stored
at −20 °C. 2995 samples (22.8%) had monoclonal κ, 1180
samples (9.0%) had monoclonal λ, and 105 samples (0.8%) had
poly LC, as detected by IFE. 12,242 of these samples were from
patients who had a known immunoglobulin paraprotein in
serum by IFE (93.5%), 641 samples had no paraprotein in
matched serum, and 207 had no serum IFE diagnosis or no
serum available. 3806 samples were received from patients
enrolled in myeloma trials and the remaining 9284 samples
were non-trial samples. Because two anti-κ FLC and two anti-λ
FLC mAbs were used in each test, the maximal concentration
detected by each anti-κ (BUCIS 01 or BUCIS 04) and each anti-λ
mAb (BUCIS 03 or BUCIS 09) was chosen as the final urine
FLC result. As a means of determining the specificity of the
mAb assay in urine, any results that were immunofixation
positive and mAb assay negative (recorded clinically as
b10 mg/L), were classed as discrepant. To ensure that
each of the anti-FLC mAbs targeted all FLC epitopes, all
discrepant samples were re-tested on the mAb assay
and by urine IFE. If a discrepancy remained, a full urine
IFE was conducted to exclude the presence of whole
paraprotein because initial IFE used anti-sera against LC
free and bound. Further investigation of matched serum
Fig. 2. A. κ and λ FLCs diagnostic ranges of Freelite™ and the mAb assay derived from the analysis of 249 plasma samples from healthy donors. Whisker boxplots
illustrate the 5%, 25%, median, 75% and 95% intervals and extreme values (b5% & >95% intervals) are dotted. The full diagnostic ranges represent 100% of the
healthy donors (n = 249) after IFE screen. The adjacent table details the κ and λ FLCs 95% median, standard deviation and reference ranges derived from the
same samples; due to a positively skewed distribution after removal of extreme outliers, z-scores were used to identify the central 95% median and reference
ranges. 2B. κ:λ FLC ratio diagnostic ranges derived from Freelite™ and the mAb assay. As above, the full diagnostic ranges represent 100% of the healthy donors
(n = 249) after IFE screen. The adjacent table details the κ:λ FLC ratio 95% reference ranges derived from these samples and, as above, after removal of outliers
these were calculated using z-scores to identify the central 95% median, standard deviation and reference ranges. *The ratio obtained by BUCIS 04 and BUCIS 09
was used for these calculations.
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available.2.11. Routine laboratory assays
Freelite™ κ and λ FLC assays were conducted on a Roche
Hitachi Modular analyser using manufacturer's instructions.
The reported working range of Freelite™ on this instrument
from the manufacturer was 3.7–56.2 mg/L for κ FLC and 5.6–
74.8 mg/L for λ FLC (Bradwell, 2008).
Urine and serum IFE was performed using Hydragel IF 2/4
gels on a Hydrasys analyser according to manufacturer's
instructions (all antisera from Sebia, France). Routine serum
IFE comprised a panel of antisera against: bound and free κ
and λ LC, IgA, IgM, and IgG. Where necessary, antisera against
IgD, IgE, and κ and λ FLCs were also used. Routine IFE on
unconcentrated urine comprised a panel of antisera against
bound and free κ and λ LC. Where necessary, antisera against
IgA, IgD, IgE, IgG, IgM and κ and λ FLCs were used. In-house
detection limits for κ and λ FLCs in unconcentrated urine
using bound and free κ and λ antisera was approximately
10 mg/L; not replicating the sensitivity of IFE in concentrated
urine (Palladini et al., 2009). The sensitivity of bound and freeκ and λ LC antisera in serum was approximately 100 mg/L
(representative images not shown).
2.12. Statistical analysis software
All statistical analyses were conducted using PASW
Statistics Version 18 (IBM, USA) with the exception of assay
linearity, batch-to-batch variability and mAb correlations with
Freelite™, which were assessed using the Microsoft Excel
Add-in Analyse-it (version 2.26, www.analyse-it.com). Spear-
man correlationswere ranked as ‘good’ between 0.75 and 0.90,
and ‘excellent’ above 0.90. All figures were produced using
SigmaPlot version 11.0 (Systat Software Inc., USA).
3. Results
3.1. Assay reference ranges
250 plasma samples from healthy donors were analysed
for κ and λ FLCs using the mAb assay and a comparison was
made between each of the anti-FLC mAbs, and to Freelite™.
All samples were pre-screened for paraproteins by routine
serum IFE analysis. IFE revealed that one sample had an IgG λ
paraprotein with λ FLC, and the sample was excluded from
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Fig. 3. Representative data from 12 concentrated urines containing κ FLC
paraproteins (top) and 9 concentrated urines containing λ FLC paraproteins
(bottom), quantitated on the mAb assay and by densitometric scanning
of urine protein electrophoresis. For each sample on the mAb assay, the
maximum value obtained by either BUCIS 01 or BUCIS 04 was used for
the for κ FLC result, and the maximum value obtained by either BUCIS 03
or BUCIS 09 was used for the λ FLC result. Linear regression (R2) and 95%
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identified elevated λ FLC and an abnormal κ:λ FLC ratio in
this sample. This finding accords with expected prevalence of
MGUS in the general population (Kyle et al., 2006). Reference
ranges for each anti-FLC mAb were similar to Freelite™ for
the remaining 249 samples (Fig. 2). The two anti-κmAbs also
had similar reference ranges to each other, with BUCIS 04
having a slightly broader reference range than BUCIS 01
(BUCIS 01: 6.46–15.10 mg/L; BUCIS 04: 4.35–19.44 mg/L).
The two anti-λmAbs were also similar, with BUCIS 03 having
a slightly broader reference range than BUCIS 09 (BUCIS 03:
4.13–19.18 mg/L; BUCIS 09: 5.19–18.87 mg/L). In terms of
the κ:λ ratio, the mAb assay had a similar range to Freelite™
(mAb assay: 0.40–1.59; Freelite™: 0.58–1.76).3.2. Assay speciﬁcity — serum samples
1000 consecutive serum samples, selected as they arrived
in the CIS for routine serum FLC analysis, were analysed using
the mAb assay and Freelite™ (Fig. 4). Overall, each anti-FLC
mAb showed good or excellent Spearman correlations with
Freelite™: anti-κ BUCIS 01 (R2 = 0.79, 95% CI 0.76–0.81),
anti-κ BUCIS 04 (R2 = 0.92, 95% CI 0.91–0.93), anti-λ BUCIS
03 (R2 = 0.87, 95% CI 0.85–0.88) and anti-λ BUCIS 09 (R2 =
0.85, 95% CI 0.84–0.87). Compared to each other, BUCIS 01
and BUCIS 04 mAbs provided a good correlation for κ FLC
(R2 = 0.78, 95% CI 0.76–0.80) and BUCIS 03 and BUCIS 09
mAbs provided an excellent correlation for λ FLC (R2 = 0.97,
95% CI 0.97–0.98). In terms of the κ:λ ratio (Fig. 5), both
Freelite™ and the mAb assay demonstrated a good correla-
tion (R2 = 0.85, 95% CI 0.83–0.86).
Individual results from each assay were then compared
to identify any discrepancies between the mAb assay and
Freelite™. For this initial clinical validation of the mAb assay,
the mean κ FLC results generated by BUCIS 01 and BUCIS 04
mAbs were used, and the λ FLC results obtained by BUCIS 03
and BUCIS 09 mAbs were used. From this process, 61
discrepancies were identified (6.1% of total samples tested),
of which there were 41 discrepant κ FLC results and 20
discrepant λ FLC results. Further investigations on these
discrepant samples revealed that elevated levels of FLC, or an
elevated FLC ratio, on the Freelite™ assay was not supported
by the mAb assay or serum IFE, and may have reflected
cross-reactivity on the Freelite™ assay with whole immuno-
globulin paraprotein or hindrance from the Freelite ‘gaps’
(see Fig. 6); for detailed assessment, see supplementary
results. Results from the mAb assay were supported by serum
IFE, as well as investigations onmatched urine and analysis of
patient history, where available. In summary, results indi-
cated that all serum samples with abnormal FLC levels, or an
abnormal κ:λ ratio, were detected by the mAb assay from
1000 consecutive serum samples. Further investigations
revealed that both anti-κ FLC mAbs (BUCIS 01 and BUCIS
04) were diagnostically similar, and either could be used to
indicate a sample containing an abnormal κ FLC level.
Similarly, both anti-λ FLC mAbs (BUCIS 03 and BUCIS 09)
were diagnostically similar, and either could be used to
indicate a sample containing an abnormal λ FLC level.
3.3. Assay speciﬁcity — urine samples
Results from 13,090 urine samples analysed routinely by
the CIS on the mAb assay and on urine IFE were compared to
assess the specificity and sensitivity of the mAbs at detecting
FLC in urine. Urine IFE was conducted using antisera against κ
and λ LCs that did not distinguish between free and bound
LC. Of the 13,090 urines, 12,242 samples were from patients
who had a known serum paraprotein, 641 samples had no
paraprotein present, and 207 had an unknown admission
diagnosis. After initial comparisons between the mAb assay
and IFE, 199 discrepancies were identified (1.52% of all
samples tested). 143 of these samples had polyclonal LC by
IFE but b10 mg/L of the relevant FLC on the mAb assay. The
other 56 samples had monoclonal LC present in the urine, but
b10 mg/L of the relevant FLC on the mAb assay. These
samples were re-tested on the mAb assay to exclude the
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Fig. 4. 1000 consecutive routine clinical serum samples analysed for κ and λ FLCs on the mAb assay and Freelite™. Results comparing the anti-κ FLC mAbs
(BUCIS 01 and BUCIS 04) and Freelite™ κ FLC are located at the top, and located at the bottom are the results obtained by the anti-λ FLC mAbs (BUCIS 03 and
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reference ranges in Fig. 2.
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full IFE analysis to distinguish between FLC and LC bound to
whole immunoglobulin. Results from this process revealed
that all samples with FLC detected by IFE were also detected
by the mAb assay. Complementary analyses of matched
serums and patient history also supported these findings. In
summary, the mAbs detected FLC in all 2995 urine samples
containing monoclonal κ FLC and all 1180 urine samples
containing monoclonal λ FLC, as detected by IFE specific
for FLC.
3.4. Assay dynamics
Assay imprecision, or CV%, was measured in pools of serum
sampleswith low,mediumand high κ orλ FLC levels. For κ FLC,
at 8.00 mg/L, 16.85 mg/L, and 238.94 mg/L, the intra-assay
CV% was 4.46%, 4.69%, and 4.85%, respectively; and the inter-
assay CV% was 6.45%, 6.50%, and 5.31%, respectively. For λ FLC,
at 7.27 mg/L, 10.38 mg/L, and 91.13 mg/L, the intra-assay CV%
was 5.69%, 4.86%, and 2.84%, respectively; and the inter-assay
CV% was 9.19%, 7.99%, and 6.96%, respectively.
Assay batch-to-batch variability was assessed by analysing
50 serum samples with varying FLC levels (κ range 3.42–
329.88 mg/L; λ range 1.09–130.51 mg/L) and the results aredisplayed in Fig. 7. All sampleswere analysed once, on separate
assay days, using three consecutive batches of anti-FLC mAbs,
calibrators and other appropriate assay reagents. Passing and
Bablok regression analysis gave slopes between 0.93–1.01 for κ
FLC and 0.86–1.05 for λ FLC. Spearman correlation coefficients
for κ FLC were ≥0.99 and for λ FLC were ≥0.96.
Representative assay linearity results are displayed in
Fig. 8. Serum samples containing high levels of either κ
(581.36, 416.37, and 256.97 mg/L) or λ (485.04, 379.41and
370.56 mg/L) FLC paraproteins were serially diluted in assay
buffer. Results indicated that assay linearity was maintained
on the monoclonal κ FLC samples between 7.61 mg/L and
568.01 mg/L, 1.94 mg/L and 410.36 mg/L, and, 6.32 mg/L and
260.78 mg/L, respectively. For the λmonoclonal FLC samples,
linearity was maintained between 1.38 mg/L and 476.1 mg/L,
1.78 mg/L and 361.72 mg/L, and, 4.45 mg/L and 381.62 mg/L,
respectively. For κ FLC, below 10 mg/L nomore than 1.45 mg/L
non-linearity was found, and above 10 mg/L no more than
16.37% non-linearity was observed. For λ FLC, below 10 mg/L
no more than 2.03 mg/L non-linearity was found, and above
10 mg/L no more than 19.0% non-linearity was found.
The assay limit of detection for each mAb was assessed by
measuring each against a κ or λ BJ protein, firstly mixed with
normal serum, and then serially diluted in assay buffer. Limit
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0.86 mg/L, BUCIS 03 was 0.72 mg/L, and BUCIS 09 was
0.52 mg/L.
Assay interference tests showed minimal assay cross-
reactivity to alternate κ or λ FLC or intact immunoglobulins,
bilirubin, haemoglobin, cholesterol or triglyceride (Fig. 9,
in supplementary data). Results demonstrated that no more
than a median 2.7 mg/L change was observed for the anti-κ
FLC mAbs, and no more than a median 3.7 mg/L change for
the anti-λ FLC mAbs.
4. Discussion
This study describes the development of four mouse
anti-human κ:λ FLC mAbs and their initial validation in a
multi-plex Luminex® immunoassay. Each of the anti-FLC
mAbs exhibited: excellent sensitivity (b1 mg/L); low batch
variation; sustained assay linearity; specificity and minimal
cross-reactivity to bound LC, or alternate FLC isotype. Each of
the mAbs provided good quantitative concordance with the
Freelite™ assay in the measurement of polyclonal FLC in
plasma from 249 healthy donors, and FLC levels in serum
from 1000 consecutive samples. Specificity and sensitivity
were further illustrated in the measurement of FLC in 13,090
urine samples tested for BJ proteins. In this set of urine
samples the mAbs detected FLC in all 2995 samples containing
monoclonal κ FLC and all 1180 samples containingmonoclonal
λ FLC, as detected by IFE. This is important because previously
describedmAbs against FLC have not been shown to detect FLCfrom substantially all neoplastic plasma cell clones (Abe et al.,
1993, 1998; Nakano and Nagata, 2003; Davern et al., 2008;
te Velthuis et al., 2011; Hoedemakers et al., 2012); many of the
mAbs that we have produced against FLC do not bind FLC from
up to a quarter of individual myeloma patients. The extent of
FLC structural diversity is reflected in the LC gene structure.
Thus, the κ immunoglobulin gene family contains 81 genes
located on chromosome 2, of which, at least 40 functional
genes are responsible for V region variability, giving rise to
at least 4 major V region types (Vκ1, Vκ2, Vκ3, and Vκ4)
(Sitnikova and Nei, 1998; Davern et al., 2008). Further, there
are 5 genes responsible for encoding the J region, and 1
constant region gene expressing 1 of 3 allotypic forms (κm1,
κm2, κm3) (Sitnikova andNei, 1998; Davern et al., 2008; Jefferis
and Lefranc, 2009). Theλ immunoglobulin gene family appears
to support more diversity, in that there are at least 40
functional genes responsible for V region variability that results
in at least 5 major V region types (Vλ1, Vλ2, Vλ3, Vλ6, and
Vλ8). Further, there are at least 5 genes responsible for
encoding the J region, and up to 7 genes for the C region that
gives rise to at least 3 C region isotypes (Cλ1, Cλ2/3, Cλ7)
(Solomon andWeiss, 1995;Davern et al., 2008). FLC diversity is
extended by somatic mutations in the encoding genes and
post-translational modifications of FLC. Given this multiplicity
of human FLC structures, it is not surprising that it is difficult to
produce mAbs that would detect the FLC from substantially all
patients and neoplastic plasma cell clones. To be clinically
reliable any new assay for FLC should be tested against a large
number of serum and urine samples to show that themAbs are
Freelite κ FLC (mg/L)
10-1 100 10 1 10 2 103 104 105
Fr
ee
lit
e
λ  
FL
C 
(m
g/L
)
10 -1
10 0
10 1
10 2
10 3
10 4
10 5
High ratio
Normal ratio
Low ratio
mAb assay κ FLC (mg/L)
m
Ab
 a
ss
a
y 
λ  
FL
C 
(m
g/
L)
High ratio
Normal ratio
Low ratio
10-1 100 10 1 10 2 103 104 105
10 -1
10 0
10 1
10 2
10 3
10 4
10 5
Fig. 6. κ and λ FLC levels in 1000 consecutive routine clinical serum samples analysed on the Freelite™ assay (top), with the so-called ‘gaps’ in Freelite™ quantitation of
FLC clearly visible (Bradwell, 2008). Illustrated, bottom, are results from the same consecutive samples generated by the mAb assay using the BUCIS 04 (anti-κ FLC)
and BUCIS 09 (anti-λ FLC) mAbs. No quantitative ‘gaps’ were observed in the results generated by these mAbs, or the other BUCIS 01 and BUCIS 03 anti-FLC mAbs
(not illustrated). In both figures above, the results were trichotomised into groups based onwhether the sample had a high, normal or low κ:λ FLC ratio generated by
BUCIS 04 and BUCIS 09; for this calculation, the ratio limits were determined using the BUCIS 04 and BUCIS 09 95% reference ranges in Fig. 2.
10 J.P. Campbell et al. / Journal of Immunological Methods 391 (2013) 1–13
k FLC Batch 1 (mg/L)
1 10 100 1000
κ
 
FL
C 
Ba
tc
he
s 
2-
3 
(m
g/L
)
1
10
100
1000
Batch 1 vs Batch 2
Batch 1 vs Batch 3
λ FLC batch 1 (mg/L)
1 10 100 1000
λ  
FL
C 
ba
tc
he
s 
2-
3 
(m
g/
L)
1
10
100
1000
Batch 1 vs Batch 2
Batch 1 vs Batch 3
Fig. 7. Batch-to-batch variation from three independent lots of anti-FLC κmAbs
(top) and λ mAbs (bottom) and other assay materials, when measuring 50
serum samples containing varying levels of FLC.
Concentration %
0 20 40 60 80 100
κ
 
FL
C 
(m
g/L
)
0
100
200
300
400
500
λ  
FL
C 
(m
g/
L)
0
100
200
300
400
500
Concentration %
0 20 40 60 80 100
Fig. 8. Linearity examples of serial dilutions of serum containing either a κ
FLC paraprotein (top) or λ FLC paraprotein (bottom); samples were serially
diluted 2-fold in assay buffer. In each figure, comparative linear (predicted)
values are represented by a dashed line and the acquired (non-linear)
titrations are represented by a black continuous line.
11J.P. Campbell et al. / Journal of Immunological Methods 391 (2013) 1–13at least close to the ideal of detecting FLC from all patients and
neoplastic plasma cell clones.
In plasma samples containing normal polyclonal FLC,
obtained from healthy donors, each of the mAbs provided
similar quantitation of absolute FLC levels. These samples
were obtained from UK blood donors, which include persons
up to the age of 65 years. It is likely that some of these donors
had MGUS, and indeed, one donor found to have an abnormal
FLC ratio detected by both the mAb assay and Freelite™, had
a 30 g/L IgG λ paraprotein. Similarly, we cannot exclude
the possibility that some donors had a degree of renal
impairment. For both polyclonal and monoclonal λ FLC in a
thousand consecutive serum samples, the two anti-λ FLC
mAbs exhibited excellent correlations with each other, and
displayed good clinical concordance with Freelite™. The
diversity in FLC repertoire may explain the more divergent
correlations demonstrated in this study between the mAb
assay and Freelite™ for highly elevated monoclonal λ FLCparaproteins (see Fig. 4). Similarly, the two anti-κ FLC mAbs
displayed good clinical concordance with each other; there
were some quantitative differences in samples with mono-
clonal FLC but each mAb identified an abnormal level of
the relevant FLC, as well as an abnormal κ:λ FLC ratio in each
of these samples. In addition, each mAb displayed good
concordance with Freelite™.
The development of precise anti-FLC mAbs, as shown in
this study, enables diversification away from existing assay
platforms and may lead to improvements in FLC assay design.
Current commercial tests, using turbidimetric and nephelo-
metric formats (Bradwell et al., 2001) have a number of well
observed limitations. Firstly, these systems are reliant on
a separate test for each κ and λ FLC measurement. This
introduces inter-test variability and reduces the precision of
the κ:λ ratio. Simultaneous measurement of both κ and λ
FLCs in our assay removes some of this inter-test variability
and should thus provide a more reliable measure of the κ:λ
ratio. To our knowledge, this is the first assay to adopt this
configuration. From a practical perspective this format is also
beneficial as a single test because it is more time and resource
efficient, and the sample volume required (b10 μL) is much
lower than typical turbidimetric and nephelometric re-
quirements, thus preserving stock sample volume. A second
12 J.P. Campbell et al. / Journal of Immunological Methods 391 (2013) 1–13problem with the format of existing serum FLC tests is
known as antigen excess or a ‘hook-effect’ and has been
documented elsewhere (Daval et al., 2007; Levinson, 2010a).
This phenomenon occurs when high levels of FLC analyte
exceed the number of available antibody binding sites thus
reducing or eliminating FLC-antibody aggregates, resulting in a
false-negative signal output. Use of a competitive inhibition
format in our assay overcomes this problem and such an
improvement is likely to improve the reliability of patient
diagnosis and monitoring. Indeed, we found no instances
where the mAbs ‘missed’ elevated FLC above 100 mg/L
(sensitivity of serum IFE), indicating that there were no
instances of antigen excess using the mAb assay in serum or
in the large numbers of urine samples tested. Our assay also
provides a larger dynamic range, better sensitivity, and
avoidance of ‘gaps’ seen in the current serum FLC assay in
Figs. 4 and 6, and discussed elsewhere (Bradwell, 2008).
In conclusion, we have developed a new method of
measuring urine and serum FLC using anti-κ and anti-λ FLC
mAbs. This method offers improved sensitivity and reliability
over existing methods that rely on sheep polyclonal antisera.
Further, the mAbs used in this study demonstrated excellent
specificity and identified FLC in 13,090 urine samples tested
for the presence of BJ proteins, normal and abnormal FLC
levels in 1000 consecutive serums samples, and normal levels
of polyclonal FLC from healthy donors. This analysis served
as an initial clinical assessment of the mAbs, and given the
effective specificity displayed, further assessment of patients
with known multiple myeloma, light chain only myeloma,
non-secretory myeloma and other FLC-relevant disorders is
now warranted. Utilisation of these mAbs in other assay
platforms should also be investigated.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jim.2013.01.014.
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